







an Open Access Journal by MDPI

Heat Shock Proteins in Cancer: Chaperones of Tumorigenesis

Guest Editors:

Prof. Dr. Michael Y. Sherman

Department of Biochemistry, Boston University School of Medicine, 72 East Concord Street K-323, Boston, MA 02118, USA

Prof. Dr. Stuart K. Calderwood

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

Deadline for manuscript submissions:

closed (30 November 2013)

Message from the Guest Editors

Dear Colleagues,

Population studies and laboratory data with cells and model organisms indicate that various heat shock proteins play an important role in the genesis and progression of many cancer types. These works led to development of inhibitors of heat shock proteins, some of which have been tested in clinical trials. Since recently we have started understanding the mechanistic aspects of the role of heat shock proteins in cancer, which hopefully will teach us how to rationally combine the inhibitors with other anti-cancer drugs and what types of cancer can be treated with these inhibitors. This issue of Cancers, "Heat shock proteins in cancer: chaperones of tumorigenesis" seeks articles which will shed new light on this topic.

Prof. Dr. Michael Y. Sherman Dr. Stuart K. Calderwood Guest Editors













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us